RESEARCH PAPER
7-Nitroindazole does not affect the anti-convulsant action of gabapentin and tiagabine in pentylenetetrazole-induced seizures in mice
 
More details
Hide details
1
Department of Pathophysiology, Medical University, Lublin, Poland
2
Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
3
First Department of Internal Medicine with Dialysis Station, County Hospital, Starachowice, Poland
4
Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland
CORRESPONDING AUTHOR
Jarogniew J. Łuszczki   

Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland.
 
J Pre Clin Clin Res. 2007;1(2):150–154
KEYWORDS
ABSTRACT
Accumulating experimental evidence indicates that nitric oxide (NO) plays an important role in the pathophysiology of seizures. The purpose of this study was to determine the effect of 7-nitroindazole (7-NI, a preferential neuronal nitric oxide synthase inhibitor) on the anticonvulsant activity of gabapentin (GBP) and tiagabine (TGB) – two newer antiepileptic drugs (AEDs) in the mouse pentylenetetrazole (PTZ)-induced seizure model. The clonic seizures in mice were evoked by subcutaneous injection of PTZ at a dose of 100 mg/kg. The clonic seizure activity was defined as clonus of the whole body lasting over 3 s, with an accompanying loss of righting reflex in mice. The anti-convulsant action of GBP and TGB against PTZ-induced seizures was expressed as median effective doses (ED50 values) of the AEDs, protecting 50% of animals tested against PTZ-induced seizures. The acute adverse-effect potentials of GBP and TGB in combination with 7-NI were evaluated by the chimney test (motor coordination). Results indicate that 7-NI administered intraperitoneally at a dose of 50 mg/kg did not significantly affect the anticonvulsant action of GBP and TGB against PTZ-induced seizures. The experimentally-derived ED50 values for GBP administered alone and in combination with 7-NI were 289 and 350 mg/kg. Similarly, the ED50 values for TGB administered alone and in combination with 7-NI were 0.7 and 0.8 mg/kg, respectively. Moreover, the with GBP (350 mg/kg) or TGB (0.8 mg/kg) did not affect motor coordination in the chimney test. In conclusion, 7-NI had no impact on the anti-convulsant activity of GBP and TGB in the mouse PTZ-induced seizure model, and did not affect motor coordination of mice challenged with the chimney test
 
REFERENCES (37)
1.
Iadecola C: Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 1997, 20, 132-139.
 
2.
Moncada S, Higgs EA: Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995, 9, 1319-1330.
 
3.
Montecot C, Borredon J, Seylaz J, Pinard E: Nitric oxide of neuronal origin is involved in cerebral blood flow increase during seizures induced by kainate. J Cereb Blood Flow Metab 1997, 17, 94-99.
 
4.
Szabo C: Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res Bull 1996, 41, 131-141.
 
5.
East SJ, Garthwaite J: NMDA receptor activation in rat hippocampus induces cyclic GMP formation through the L-arginine-nitric oxide pathway. Neurosci Lett 1991, 123, 17-19.
 
6.
Rondouin G, Lerner-Natoli M, Manzoni O, Lafon-Cazal M, Bockaert J: A nitric oxide (NO) synthase inhibitor accelerates amygdala kindling. Neuroreport 1992, 3, 805-808.
 
7.
Starr MS, Starr BS: Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthesis inhibitor L-NAME. Pharmacol Biochem Behav 1993, 45, 321-325.
 
8.
Penix LP, Davis W, Subramaniam S: Inhibition of NO synthase increases the severity of kainic acid-induced seizures in rodents. Epilepsy Res 1994, 18, 177-184.
 
9.
Przegaliński E, Baran L, Siwanowicz J: The role of nitric oxide in chemically- and electrically-induced seizures in mice. Neurosci Lett 1996, 217, 145-148.
 
10.
Marangoz C, Ayyildiz M, Ağar E: Evidence that sodium nitroprusside possesses anticonvulsant effects mediated through nitric oxide. Neuroreport 1994, 5, 2454-2456.
 
11.
Mollace V, Bagetta G, Nistico G: Evidence that L-arginine possesses proconvulsant effects mediated through nitric oxide. Neuroreport 1991, 2, 269-272.
 
12.
Proctor MR, Fornai F, Afshar JK, Gale K: The role of nitric oxide in focally-evoked limbic seizures. Neuroscience 1997, 76, 1231-1236.
 
13.
De Sarro G, Di Paola ED, De Sarro A, Vidal MJ: L-arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex. Eur J Pharmacol 1993, 230, 151-158.
 
14.
De Sarro GB, Donato Di Paola E, De Sarro A, Vidal MJ: Role of nitric oxide in the genesis of excitatory amino acid-induced seizures from the deep prepiriform cortex. Fundam Clin Pharmacol 1991, 5, 503-511.
 
15.
Osonoe K, Mori N, Suzuki K, Osonoe M: Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazolinduced seizures in rats. Brain Res 1994, 663, 338-340.
 
16.
Kirkby RD, Carroll DM, Grossman AB, Subramaniam S: Factors determining proconvulsant and anticonvulsant effects of inhibitors of nitric oxide synthase in rodents. Epilepsy Res 1996, 24, 91-100.
 
17.
Baran L, Siwanowicz J, Przegaliński E: Effect of nitric oxide synthase inhibitors and molsidomine on the anticonvulsant activity of some antiepileptic drugs. Pol J Pharmacol 1997, 49, 363-368.
 
18.
De Sarro G, Gareri P, Falconi U, De Sarro A: 7-Nitroindazole potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Eur J Pharmacol 2000, 394, 275-288.
 
19.
Łuszczki JJ, Czuczwar M, Gawlik P, Sawiniec-Pozniak G, Czuczwar K, Czuczwar SJ: 7-Nitroindazole potentiates the anticonvulsant action of some second-generation antiepileptic drugs in the mouse maximal electroshock-induced seizure model. J Neural Transm 2006, 113, 1157- 1168.
 
20.
Łuszczki JJ, Sacharuk A, Wojciechowska A, Andres MM, Dudra- Jastrzebska M, Mohamed M, Sawicka KM, Kozińska J, Czuczwar SJ: 7- Nitroindazole enhances dose-dependently the anticonvulsant activities of conventional antiepileptic drugs in the mouse maximal electroshockinduced seizure model. Pharmacol Rep 2006, 58, 660-671.
 
21.
Smith SE, Man CM, Yip PK, Tang E, Chapman AG, Meldrum BS: Anticonvulsant effects of 7-nitroindazole in rodents with reflex epilepsy may result from L-arginine accumulation or a reduction in nitric oxide or L-citrulline formation. Br J Pharmacol 1996, 119, 165-173.
 
22.
Tutka P, Luszczki J, Kleinrok Z, Arent K, Wielosz M: Molsidomine enhances the protective activity of valproate against pentylenetetrazoleinduced seizures in mice. J Neural Transm 2002, 109, 455-466.
 
23.
Han D, Yamada K, Senzaki K, Xiong H, Nawa H, Nabeshima T: Involvement of nitric oxide in pentylenetetrazole-induced kindling in rats. J Neurochem 2000, 74, 792-798.
 
24.
Borowicz KK, Luszczki J, Kleinrok Z, Czuczwar SJ: 7-Nitroindazole, a nitric oxide synthase inhibitor, enhances the anticonvulsive action of ethosuximide and clonazepam against pentylenetetrazol-induced convulsions. J Neural Transm 2000, 107, 1117-1126.
 
25.
Borowicz KK, Kleinrok Z, Czuczwar SJ: Influence of 7-nitroindazole on the anticonvulsive action of conventional antiepileptic drugs. Eur J Pharmacol 1997, 331, 127-132.
 
26.
Rajasekaran K, Jayakumar R, Venkatachalam K: Increased neuronal nitric oxide synthase (nNOS) activity triggers picrotoxin-induced seizures in rats and evidence for participation of nNOS mechanism in the action of antiepileptic drugs. Brain Res 2003, 979, 85-97.
 
27.
Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998, 29, 233-249.
 
28.
Czuczwar SJ, Patsalos PN: The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001, 15, 339-350.
 
29.
Schachter SC: Tiagabine. Epilepsia 1999, 40(5), 17-22.
 
30.
Loscher W, Honack D, Fassbender CP, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8, 171-189.
 
31.
Loscher W, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices. Epilepsy Res 1991, 9, 1-10.
 
32.
Łuszczki JJ, Szadkowski M, Czuczwar SJ: Effect of NG-nitro-L-arginine on the anticonvulsive action of four second-generation antiepileptic drugs in pentetrazole-induced clonic seizures in mice. Pharmacol Rep 2007, 59, 467-473.
 
33.
Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949, 96, 99-113.
 
34.
Łuszczki JJ, Czuczwar SJ: Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol 2004, 369, 434-446.
 
35.
Łuszczki JJ, Czuczwar SJ: Isobolographic characterisation of interactions among selected newer antiepileptic drugs in the mouse pentylenetetrazole-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 2005, 372, 41-54.
 
36.
Boissier JR, Tardy J, Diverres JC: Une nouvelle methode simple pour explorer l’action ≪tranquilisante≫: le test de la cheminee. Med Exp (Basel) 1960, 3, 81-84.
 
37.
Łuszczki JJ, Czuczwar SJ: Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31, 529- 538.
 
eISSN:1898-7516
ISSN:1898-2395